The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Novo Nordisk A/S (NYSE:NVO) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy ...

Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, the second ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk ...